Improving Colorectal Cancer Screening in Racially Diverse Zip Codes Using Navigation and Machine Learning (PCSNaP)
CompletedResults postedLast updated 11 February 2026
What this trial tests
trial testing Machine Learning Algorithm with Existing Penn Medicine CRC Patient Navigation Program in Colorectal Cancer in 385 participants. Completed in 1 November 2024.
Eligibility, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Enrollment in Navigator Program (Feasibility)Primary· During the three month enrollment period
Number of patients that participate in the navigation program
Group
Value
95% CI
Patients Residing in 18 Zip Codes in Western and Southwestern Philadelphia
79
Completion of Colorectal Cancer ScreeningPrimary· Within the three month enrollment period and three month follow-up period
Number of patients that have completed their colonoscopy or Fecal Immunochemical Test (FIT)
Group
Value
95% CI
Patients Residing in 18 Zip Codes in Western and Southwestern Philadelphia
92
Controls
79
Number of Participants With Adenoma DetectionPrimary· Within the three month enrollment period and three month follow-up period
Rate of adenomas after completion of colonoscopy
Group
Value
95% CI
Patients Residing in 18 Zip Codes in Western and Southwestern Philadelphia
21
Controls
15
Sponsor's own description
The overarching goal of the "PCSNaP" Research Study is to support the Abramson Cancer Center (ACC) of the University of Pennsylvania in carrying out its mission to increase colorectal cancer (CRC) screening completion among high-risk individuals living in a persistent poverty county by designing, conducting, disseminating and evaluating an electronic health record-based automated identification program to target effective, culturally-sensitive CRC screening navigation to individuals who have not completed an ordered colonoscopy or fecal immunochemical test (FIT).
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino
· Phase 3
· recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
· Phase 1, PHASE2
· recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
· Phase 1, PHASE2
· recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes
· recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes
· recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
· Phase 1
· not yet recruiting
NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma
· Phase 2
· not yet recruiting
NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE)
· NA
· not yet recruiting
NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery
· NA
· recruiting
NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
Last refreshed: 11 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05383976.